Caris Life Sciences (NASDAQ:CAI) Director Jeff Vacirca Purchases 31,050 Shares

Posted by Stanley Muller on May 13th, 2026

Caris Life Sciences, Inc. (NASDAQ:CAI – Get Free Report) Director Jeff Vacirca acquired 31,050 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was bought at an average price of $16.15 per share, with a total value of $501,457.50. Following the purchase, the director directly owned 49,671 shares of the company’s stock, valued at $802,186.65. This represents a 166.75% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Caris Life Sciences Price Performance

NASDAQ CAI opened at $16.76 on Wednesday. The company has a quick ratio of 7.35, a current ratio of 7.05 and a debt-to-equity ratio of 0.64. Caris Life Sciences, Inc. has a 1 year low of $15.70 and a 1 year high of $42.50. The firm has a market capitalization of $4.74 billion and a P/E ratio of -2.20. The company has a fifty day moving average of $18.97.

Caris Life Sciences (NASDAQ:CAI – Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.27. Caris Life Sciences had a net margin of 3.75% and a return on equity of 98.28%. The company had revenue of $292.89 million during the quarter, compared to the consensus estimate of $281.00 million. During the same quarter in the prior year, the firm posted ($1.73) earnings per share. Caris Life Sciences’s revenue for the quarter was up 125.4% on a year-over-year basis. On average, research analysts expect that Caris Life Sciences, Inc. will post 0.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Piper Sandler assumed coverage on shares of Caris Life Sciences in a research note on Friday, April 10th. They issued a “neutral” rating and a $21.00 price objective for the company. Jefferies Financial Group started coverage on shares of Caris Life Sciences in a research note on Monday, April 13th. They set a “buy” rating and a $28.00 target price for the company. BTIG Research decreased their target price on shares of Caris Life Sciences from $38.00 to $32.00 and set a “buy” rating for the company in a research note on Friday, May 8th. JPMorgan Chase & Co. decreased their target price on shares of Caris Life Sciences from $35.00 to $30.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Finally, The Goldman Sachs Group started coverage on shares of Caris Life Sciences in a research note on Wednesday, April 1st. They set a “buy” rating and a $27.00 target price for the company. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Caris Life Sciences has a consensus rating of “Moderate Buy” and an average target price of $27.56.

View Our Latest Stock Analysis on CAI

Institutional Investors Weigh In On Caris Life Sciences

Several hedge funds have recently made changes to their positions in the business. Global Retirement Partners LLC raised its holdings in Caris Life Sciences by 99,900.0% during the fourth quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock worth $27,000 after purchasing an additional 999 shares in the last quarter. Olistico Wealth LLC purchased a new position in Caris Life Sciences during the fourth quarter worth about $31,000. PNC Financial Services Group Inc. raised its holdings in Caris Life Sciences by 839.4% during the first quarter. PNC Financial Services Group Inc. now owns 1,644 shares of the company’s stock worth $29,000 after purchasing an additional 1,469 shares in the last quarter. MetLife Investment Management LLC raised its holdings in Caris Life Sciences by 84.0% during the fourth quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock worth $45,000 after purchasing an additional 755 shares in the last quarter. Finally, Fifth Third Bancorp purchased a new position in Caris Life Sciences during the first quarter worth about $31,000.

Caris Life Sciences Company Profile

(Get Free Report)

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.